Alkermes plc (ALKS)

NMS – Real Time Price. Currency in USD

38.29

+2.82 (7.95%)

At close: May 12, 2026, 4:00 PM EDT

38.65

+0.36 (0.94%)

Pre-market: May 13, 2026, 9:02 AM EDT

12.05.2026

Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles

Alkermes Inc. plc (NASDAQ:ALKS) stock is trading higher on Tuesday following the announcement of positive topline results from the REVITALYZ phase 3 study evaluating LUMRYZ extended-release oral suspension for excessive daytime sleepiness associated with idiopathic hypersomnia.

12.05.2026

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the REVITALYZ℠ double-blind, placebo-controlled, randomized withdrawal, multicenter phase 3 study evaluating the investigational use of LUMRYZ® (sodium oxybate) extended-release oral suspension in adults with idiopathic hypersomnia (IH). LUMRYZ met the study's primary endpoint, demonstrating statistically significant improvements in excessive daytime sleepiness compared to placebo as measured by t.

06.05.2026

Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results

Alkermes (NASDAQ:ALKS) reported upbeat results for the first quarter on Tuesday.

06.05.2026

Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises

ALKS beats Q1 estimates as strong proprietary drug sales lift revenues by 28%, sending shares higher, while Lumryz adds a fresh growth driver.

06.05.2026

Alkermes: A Sleep Medicine Platform Hidden Inside A Mature CNS Company

Alkermes is transitioning into an integrated neuroscience and sleep medicine company, highlighted by the Avadel acquisition and LUMRYZ integration. Q1 2026 results show proprietary product sales rising to $338.1M, with LUMRYZ contributing $39.5M post-acquisition; adjusted EBITDA improved to $80.3M. Management projects 2026 revenues of $1.73–$1.84B, with four commercial products each targeting over $300M in annual net sales.

05.05.2026

Alkermes plc (ALKS) Q1 2026 Earnings Call Transcript

05.05.2026

Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Alkermes (ALKS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Videos

No Data

There is no data to display

Press releases

12.05.2026

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

05.05.2026

Alkermes plc Reports First Quarter 2026 Financial Results

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended March 31, 2026 and financial expectations for full year 2026. To view the detailed first quarter 2026 earnings press release and presentation, please visit the company's investor relations website at https://investor.alkermes.com. Alkermes will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) today to discuss these financial results and expectations and prov.

14.04.2026

Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the publication of a 56-week post hoc analysis of the effects of LYBALVI® (olanzapine and samidorphan) on negative symptoms in adults living with schizophrenia in the peer-reviewed publication The Journal of Clinical Psychiatry. The analysis—titled “The Efficacy of Olanzapine/Samidorphan on Negative Symptoms: A Post Hoc Analysis of 56-Week Treatment in Patients With Schizophrenia”—found that treatment with LYBALVI was associat.

01.04.2026

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Alixorexton is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, NT2 and idiopathic hypersomnia (IH). The Brilliance Studies program consists of three 12-.

Alkermes plc (ALKS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Alkermes plc (ALKS)

Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results

Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises

Alkermes: A Sleep Medicine Platform Hidden Inside A Mature CNS Company

Alkermes plc (ALKS) Q1 2026 Earnings Call Transcript

Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Videos

No Data

Press releases

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

Alkermes plc Reports First Quarter 2026 Financial Results

Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results

Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises

Alkermes: A Sleep Medicine Platform Hidden Inside A Mature CNS Company

Alkermes plc (ALKS) Q1 2026 Earnings Call Transcript

Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Videos

No Data

Press releases

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

Alkermes plc Reports First Quarter 2026 Financial Results

Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

Search stocks

Alkermes plc (ALKS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Alkermes plc (ALKS)

Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results

Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises

Alkermes: A Sleep Medicine Platform Hidden Inside A Mature CNS Company

Alkermes plc (ALKS) Q1 2026 Earnings Call Transcript

Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Videos

No Data

Press releases

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

Alkermes plc Reports First Quarter 2026 Financial Results

Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

Alkermes Gains Momentum After Sleep Disorder Trial Clears Key Hurdles

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results

Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises

Alkermes: A Sleep Medicine Platform Hidden Inside A Mature CNS Company

Alkermes plc (ALKS) Q1 2026 Earnings Call Transcript

Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Videos

No Data

Press releases

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

Alkermes plc Reports First Quarter 2026 Financial Results

Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2